These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28683788)

  • 1. Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report.
    Awanami Y; Fukuda M; Nonaka Y; Takashima T; Matsumoto K; Yamasaki M; Miyazono M; Ikeda Y
    BMC Nephrol; 2017 Jul; 18(1):221. PubMed ID: 28683788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hyperlipidemia with proprotein convertase subtilisin/kexin type 9 inhibitor in a patient with nephrotic syndrome: a case report.
    Choi HS; Kim CS; Ma SK; Kim SW; Bae EH
    Ann Palliat Med; 2020 Jul; 9(4):2357-2360. PubMed ID: 32648458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report.
    Kongmalai T; Chuanchaiyakul N; Srinoulprasert Y; Thongtang N
    J Med Case Rep; 2023 Mar; 17(1):89. PubMed ID: 36899379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective improvement of minimal change nephrotic syndrome with uncontrollable high low-density lipoprotein cholesterol level using evolocumab accompanied by the development of acute pancreatitis.
    Asai R; Kaneko T; Seki M; Tsuruoka S
    CEN Case Rep; 2020 Nov; 9(4):333-337. PubMed ID: 32358739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy.
    Busuioc RM; Covic A; Kanbay M; Banach M; Burlacu A; Mircescu G
    Nephrol Dial Transplant; 2020 Oct; 35(10):1663-1674. PubMed ID: 31157893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
    Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
    J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.
    Lappegård KT; Kjellmo CA; Ljunggren S; Cederbrant K; Marcusson-Ståhl M; Mathisen M; Karlsson H; Hovland A
    Transfus Apher Sci; 2018 Feb; 57(1):91-96. PubMed ID: 29398508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A safety evaluation of evolocumab.
    Roth EM
    Expert Opin Drug Saf; 2018 Jan; 17(1):99-106. PubMed ID: 28988500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
    Koren MJ; Lundqvist P; Bolognese M; Neutel JM; Monsalvo ML; Yang J; Kim JB; Scott R; Wasserman SM; Bays H;
    J Am Coll Cardiol; 2014 Jun; 63(23):2531-2540. PubMed ID: 24691094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
    Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
    Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Podocytes in Mouse Nephrotic Syndrome.
    Suzuki T; Iyoda M; Kanazawa N; Tachibana S; Honda H
    Lab Invest; 2023 Sep; 103(9):100199. PubMed ID: 37331628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.
    Sattar N; Toth PP; Blom DJ; Koren MJ; Soran H; Uhart M; Elliott M; Cyrille M; Somaratne R; Preiss D
    Am J Cardiol; 2017 Nov; 120(9):1521-1527. PubMed ID: 28844508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
    Haas ME; Levenson AE; Sun X; Liao WH; Rutkowski JM; de Ferranti SD; Schumacher VA; Scherer PE; Salant DJ; Biddinger SB
    Circulation; 2016 Jul; 134(1):61-72. PubMed ID: 27358438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
    Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
    J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.